BioPharma Reporter
NOVEMBER 21, 2022
Oramed Pharmaceuticals, a company focused on the development of oral drug delivery platforms, has signed an exclusive commercial distribution agreement for the Republic of Korea with local player, Medicox Co Ltd, in relation to its oral insulin candidate.
XTalks
SEPTEMBER 23, 2020
Being hailed as the world’s shortest and thinnest needle for insulin injection, Droplet Micron has recently been introduced into the pen needle market by HTL (High Tech Lab)-STREFA, Inc. These are important feature innovations for those that depend on insulin injections.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
APRIL 29, 2022
For many patients with type 2 diabetes, having to inject basal insulin every day is a burdensome fact of life, but Novo Nordisk is trying to change that. cases of hypoglycaemia per year with insulin icodec, versus 0.27 events for the once-daily drug. In absolute terms, there were 0.73
pharmaphorum
FEBRUARY 3, 2022
There is a rising demand for vaccines, insulin, and many modern medicines used to treat cancer and other chronic diseases. As biologics are mainly administered through the injectable route, the significant growth in the biologics market is expected to drive the injectable drug delivery and prefilled syringe market in the coming years.
pharmaphorum
JANUARY 12, 2023
Oramed Pharma has conceded defeat in its attempt to bring an oral formulation of insulin to market for people with type 2 diabetes, after its ORMD-0801 candidate missed the mark in a phase 3 trial. The post Phase 3 trial dashes Oramed’s oral insulin hopes appeared first on.
XTalks
FEBRUARY 24, 2021
The injection experience is an often-overlooked aspect in insulin administration. For many daily insulin users, the experience is an important one, as it is directly related to quality of life and medication compliance. Traditional needles on the market range between 8 and 12.5
Roots Analysis
MARCH 21, 2022
However, several drug delivery devices that enable patients to self-administer their respective medications are now available. Subcutaneous biologics – current market landscape. Subcutaneous drug delivery systems – the helping hand for patients. Of these, 50 players have approved subcutaneous biologics.
Expert insights. Personalized for you.
95 
Let's personalize your content